Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1...

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Triple-negative breast cancer (TNBC) treatment often involves anthracyclines, but resistance mechanisms, particularly to epirubicin, remain poorly understood.
• Identifying novel molecular players is crucial for overcoming epirubicin resistance in TNBC.

Purpose of the Study:

• To identify novel long noncoding RNAs (lncRNAs) involved in epirubicin resistance in TNBC.
• To elucidate the functional role of a newly identified lncRNA, lnc005620, in TNBC chemoresistance.

Main Methods:

• Established an epirubicin-resistant TNBC cell line (MDA-MB-231 Epi-R).
• Utilized RNA sequencing to identify differentially expressed lncRNAs.
• Performed gain- and loss-of-function studies for lnc005620.
• Employed iTRAQ proteomics to analyze protein expression changes.
• Validated integrin β1 as a downstream target of lnc005620.

Main Results:

• Identified 12 differentially expressed lncRNAs, including a novel intronic lncRNA, lnc005620, highly expressed in resistant cells and TNBC tissues.
• lnc005620 demonstrated an oncogenic role, partially reducing epirubicin's effectiveness in TNBC cells.
• Integrin family members (integrin β4, β1, α6) were upregulated in resistant cells, with integrin β1 validated as a downstream target of lnc005620.

Conclusions:

• The novel lncRNA lnc005620 promotes TNBC progression and epirubicin chemoresistance.
• lnc005620 exerts its effects via the integrin β1 signaling pathway.
• lnc005620 represents a promising therapeutic target for improving epirubicin treatment outcomes in TNBC.